MX2022015651A - Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos. - Google Patents

Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos.

Info

Publication number
MX2022015651A
MX2022015651A MX2022015651A MX2022015651A MX2022015651A MX 2022015651 A MX2022015651 A MX 2022015651A MX 2022015651 A MX2022015651 A MX 2022015651A MX 2022015651 A MX2022015651 A MX 2022015651A MX 2022015651 A MX2022015651 A MX 2022015651A
Authority
MX
Mexico
Prior art keywords
conjugates
systems
nlp
nanolipoprotein
methods
Prior art date
Application number
MX2022015651A
Other languages
English (en)
Inventor
Whitney Binder
Craig D Blanchette
Martine A Darwish
Rami Hannoush
Xinxin Gao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022015651A publication Critical patent/MX2022015651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a conjugados de partícula de nanolipoproteína que comprenden al menos conjugados de un polipéptido y partícula de nanolipoproteína que comprenden al menos un péptido corto de entre 20-60 aminoácidos de longitud. También se proporcionan composiciones y sistemas relacionados, y procedimientos de preparación y uso de los mismos. En particular, se proporcionan conjugados de partícula de nanolipoproteína (NLP) con fragmentos de unión a antígeno (Fab), donde la NLP comprende una bicapa de lípidos formadores de membrana rodeada por proteínas de andamio, y los Fab están conjugados a una o ambas superficies de la bicapa. En algunos modos de realización, los conjugados (NLP) comprenden además un péptido corto de 20-60 aminoácidos de longitud. Los conjugados, y las composiciones y sistemas relacionados, muestran en general una buena estabilidad y capacidad de fabricación, conservan la actividad de unión a antígeno, y pueden mejorar la potencia de unión a antígeno, lo que proporciona plataformas versátiles para la administración de Fab y tratamientos y diagnósticos basados en Fab, así como lo que proporciona plataformas estables para administrar otros agentes terapéuticos y/o de diagnóstico.
MX2022015651A 2020-06-11 2021-06-10 Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos. MX2022015651A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038075P 2020-06-11 2020-06-11
US202163151591P 2021-02-19 2021-02-19
PCT/US2021/036878 WO2021252803A1 (en) 2020-06-11 2021-06-10 Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same

Publications (1)

Publication Number Publication Date
MX2022015651A true MX2022015651A (es) 2023-01-16

Family

ID=76744974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015651A MX2022015651A (es) 2020-06-11 2021-06-10 Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos.

Country Status (12)

Country Link
US (1) US20240059755A1 (es)
EP (1) EP4164693A1 (es)
JP (1) JP2023529203A (es)
KR (1) KR20230023727A (es)
CN (1) CN115803063A (es)
AU (1) AU2021289738A1 (es)
BR (1) BR112022025227A2 (es)
CA (1) CA3183808A1 (es)
IL (1) IL298878A (es)
MX (1) MX2022015651A (es)
TW (1) TW202214307A (es)
WO (1) WO2021252803A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023269666A1 (en) * 2022-05-13 2024-11-28 Kisbee Therapeutics, Inc. Apoe lipoprotein systems
CN121358763A (zh) * 2023-06-15 2026-01-16 Rnagene公司 包括载脂蛋白质或其片段的融合蛋白质和其用途
CN121293315A (zh) * 2025-09-26 2026-01-09 南开大学 纳米磷脂盘中bcma全长受体的构建方法及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US8883729B2 (en) 2008-05-22 2014-11-11 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions, methods and systems
EP2890389A1 (en) 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017155837A1 (en) 2016-03-07 2017-09-14 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for improved drug loading
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11491215B2 (en) * 2018-05-24 2022-11-08 Lawrence Livermore National Security, Llc Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Also Published As

Publication number Publication date
JP2023529203A (ja) 2023-07-07
BR112022025227A2 (pt) 2023-01-03
AU2021289738A1 (en) 2022-12-15
CA3183808A1 (en) 2021-12-16
WO2021252803A1 (en) 2021-12-16
TW202214307A (zh) 2022-04-16
CN115803063A (zh) 2023-03-14
IL298878A (en) 2023-02-01
US20240059755A1 (en) 2024-02-22
KR20230023727A (ko) 2023-02-17
EP4164693A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
MX2022015651A (es) Conjugados de nanolipoproteina-polipeptido y composiciones, sistemas y procedimientos mediante el uso de los mismos.
WO2008145137A3 (en) Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
Bansal et al. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo
WO2004004798A3 (en) Central airway administration for systemic delivery of therapeutics
TN2011000229A1 (en) Antibody formulation
WO2005094420A3 (en) Materials and methods for treatment of inflammatory and cell proliferation disorders
JP2022513223A5 (es)
WO2005070138A3 (en) O-linked glycosylation of peptides
WO2003077834A3 (en) Central airway administration for systemic delivery of therapeutics
WO2008090958A1 (ja) ドメイン交換された遺伝子組換え抗体組成物
EP2266599A3 (en) Therapeutic composition with a botulinum neurotoxin
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO2006020580A3 (en) Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
JO2824B1 (en) Antibody glycosylate in the changing region
WO2007147001A3 (en) Lyophilized formulations of anti-egfr antibodies
EP4534107A3 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
WO2007117469A3 (en) Compositions of less immunogenic and long-circulating protein-lipid complexes
WO2006002079A3 (en) Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
Bushinsky et al. Treatment of secondary hyperparathyroidism: results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor
WO2018045376A3 (en) Functionally modified polypeptides and radiobiosynthesis
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist